A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression

Summary

The purpose of this study is to evaluate the efficacy of JNJ-67953964 compared to placebo when administered as adjunctive treatment in participants with Major Depressive Disorder (MDD) partially responsive to selective serotonin reuptake inhibitor/ serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) treatment in terms of reduction of symptoms of depression, as assessed by the change from baseline on the Montgomery Asberg Depression Rating Scale (MADRS) in non-responders during the placebo lead-in period.

Timeline

Start

2018-07-16

Primary completion

2020-05-06

Completion

2020-05-06

Outcome

Met primary endpoint

registry p = 0.0443; Least Squares Mean Difference -2.1 NCT03559192 ↗

Drugs

Indications